Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Yuan Bai

Showing results (101-110 of 139) with videos related to

Pageof 14
Sort By:
Leukemia Research|January 2, 2013
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3Po-Han Lin, Ching-Chan Lin, Hwai-I Yang, et al.
Cancer Medicine|July 4, 2023
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort studyChih-Chieh Yen, Yi-Hsin Yang, Hsiu-Ying Ku, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohortI-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
American Journal of Cancer Research|December 12, 2022
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinomaNai-Jung Chiang, Yan-Shen Shan, Chung-Pin Li, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
Cancer Investigation|July 1, 2006
High prevalence of SV40 infection in patients with nodal non-Hodgkin's lymphoma but not acute leukemia independent of contaminated polio vaccines in TaiwanPo-Min Chen, Chueh-Chuan Yen, Muh-Hwa Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric CancerNick Pavlakis, Kohei Shitara, Katrin Sjoquist, et al.
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
Pageof 14

Showing results (101-110 of 139) with videos related to

Sort By:
Pageof 14
Leukemia Research|January 2, 2013
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3Po-Han Lin, Ching-Chan Lin, Hwai-I Yang, et al.
Cancer Medicine|July 4, 2023
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort studyChih-Chieh Yen, Yi-Hsin Yang, Hsiu-Ying Ku, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohortI-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
American Journal of Cancer Research|December 12, 2022
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinomaNai-Jung Chiang, Yan-Shen Shan, Chung-Pin Li, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
Cancer Investigation|July 1, 2006
High prevalence of SV40 infection in patients with nodal non-Hodgkin's lymphoma but not acute leukemia independent of contaminated polio vaccines in TaiwanPo-Min Chen, Chueh-Chuan Yen, Muh-Hwa Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric CancerNick Pavlakis, Kohei Shitara, Katrin Sjoquist, et al.
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
Pageof 14